

Prof. Mario Roselli Biosketch

Mario Roselli received his M.D. in 1983. Specialist in Oncology (1986) and in Nuclear Medicine (1992), he is currently Head of Medical Oncology of the University Hospital Tor Vergata and Associated Professor in Medical Oncology at the Department of Systems Medicine, School of Medicine University of Rome "Tor Vergata", Italy. Prof. Roselli has participated as Principal Investigator (PI) and/or co-investigator to several clinical projects, sponsored and granted either by Government Institutions or private Companies. Among the funded projects of which Dr. Roselli has been PI, the "MCC - Medical Care Continuity" sponsored by the European Community (2004-2008) is of great interest in the context of the aims and mission pursued in the "continuous care trial" established in the Medical Oncology ward he directs. The project, aimed at establishing a telemedicine network between various European countries (France, Belgium, Italy and Poland) to ensure the continuity of care of cancer outpatients receiving active chemotherapy. Following this experience, in 2009, as the Chief of the Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Prof. Roselli established a collaboration agreement with the San Raffaele Palliative Care Centers. Over this period, an interdisciplinary team has been refined to provide integrated oncologic, medical, and supportive care services for patients with cancer disease and their families, from diagnosis to palliative care. This has been qualified by an ISO 9001-2008 certificate. The entire project has also been rewarded in 2012 and in 2015 with the certificate award for "designated centers of integrated oncology and palliative care by the European Society for Medical Oncology" (www.esmo.org). Prof. Roselli has been also actively involved in clinical and translational studies which have lead to the publication of 185 publications in international peer journals with a total impact factor equal to 651 and an H-Index of 30. Among these publications, of particular relevance for the project here presented are those published within the "Programma Straordinario Oncologia – Alleanza Contro il Cancro (ACC 2008-2011) - WP3" - "Clinical Database and Biobank for the study of elderly neoplastic patients and age-related pathologies" which has set as its primary goal the activation and implementation of a biobank dedicated to elderly cancer patients with or without abnormalities of glucose metabolism and, later, has extended its interest to cancer-related pathologies such as venous thromboembolism. Finally, as part of an active collaboration with the Laboratory of Tumor Immunology and Biology of the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, Prof. Roselli has been involved in the investigation of novel strategies for cancer vaccines, such as the characterization of the T-box transcription factor Brachyury as a driver of epithelial-to-mesenchymal transition in human carcinoma cells, aiming to the development of Brachyury-based immunotherapeutic approaches for the treatment of cancer.



Rome, _____